Company profile

NOXXON Pharma NV is a clinical-stage biopharmaceutical company specialized in the research and development of therapeutic products intended for the treatment of cancers. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD to study NOX-A12 combined with MSD's anti-PD-1 checkpoint-inhibiting antibody Keytruda® in pancreatic and colorectal cancer.

Source: Cofisem - Last Update: 23 Nov 2018
Key Executives
Chief Executive Officer Aram Mangasarian
Investor Relations Alexia Faure
Source: Cofisem - Last Update: 23 Nov 2018
Key figures
Millenium 2017 2016 2015 2014
Net sales 83 43 25
Income from ordinary activities 83 43 25
Operating income -4.730 -8.599 -14.830 -13.166
Cost of net financial indebtedness
Equity-Accounted companies' contribution to results
Net profit from discontinued activities
Net income -5.390 -10.752 -16.102 -13.798
Net income (group share) -5.385 -10.747 -16.102 -13.798
Fiscal year end 12,17 12,16 12,15 12,14
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 23 Nov 2018
Shareholder information
Acuitas Capital 35,9 %
Kreos Capital 12,7 %
TVM Capital 4,3 %
DEWB 3,4 %
NGN BioMed 2,8 %
Others 40,9 %
Source: Cofisem - Last Update: 27 Apr 2018

Address

NOXXON Pharma NV

Max-Dohrn-Strasse 8-10
DE-10589 Berlin, Berlin
Germany
Phone number: +49 30 726247 0
Source: Cofisem - Last Update: 23 Nov 2018

Contact

Alexia Faure
Phone number: +33 (0)1 44 71 98 51
Source: Cofisem - Last Update: 23 Nov 2018